Baxter International Inc. (NYSE:BAX) announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”